pp-065 Injection
Dossier type
US CTD
Dossier status
Under development
Country of origin
Canada
Comments
"Indication: Vitiligo, targeting immune-driven melanocyte destruction and chronic inflammatory pathways associated with depigmented skin lesions.
Clinical stage: Phase 2 clinical development.
Modality: Monoclonal antibody
Mechanism / Target: Anti-CXCL10 monoclonal antibody designed to block CXCL10-mediated recruitment and activation of autoreactive T cells implicated in melanocyte loss.
Route / form: Systemic administration (formulation not publicly disclosed).
Differentiation: First-in-class CXCL10-targeting approach aiming to modify underlying autoimmune processes in vitiligo, offering a steroid-free mechanism with potential to restore repigmentation and limit disease progression."
Manufacturer #38616
A clinical-stage biopharmaceutical company developing innovative therapies for inflammatory and immune-related diseases, with a focus on dermatology and serious respiratory conditions. It advances host-directed biologics and small molecule programs through global clinical studies and strategic partnerships. The organization targets unmet needs with novel mechanisms beyond standard treatments.